Real-world evidence isn't usually used for regulatory decisions, but the FDA is poised to start using it more, and there are challenges to using real-world data in clinical trials that will need to be navigated, said Nat Turner, co-founder and CEO of Flatiron Health.
Real-world evidence isn't usually used for regulatory decisions, but the FDA is poised to start using it more, and there are challenges to using real-world data in clinical trials that will need to be navigated, said Nat Turner, co-founder and CEO of Flatiron Health.
Transcript (slightly modified)
What are the challenges of using real-world data in clinical trials and getting the FDA to allow its use?
Large numbers, so you need a lot of it, you have to have tens of thousands of patients for certain use cases. FDA needs to apply, and they are, and it’s not necessarily randomized, although there are ways you can do that. It’s not necessarily prospective data so you need to think through quality control and methods for how you process that data. Probably a lot of human review at various steps of the way to make sure you’re interpreting things correctly.
Ultimately, real-world evidence is not really used for regulatory decisions right now, it’s more used for publications, supplemental data. The FDA will have to be the one ultimately to say: hey we’re going to make a regulatory—maybe approve an expansion of a label, for example, that’s going to have to be them. 21st Century Cures, which was the last bill President Barack Obama signed, gave them the runway, kind of the box to play in which said: use real-world evidence for was many things as you can. We’re going to see, and the new director, Scott Gottlieb is doing a lot of very cool things to push that agenda. We’ll see what happens.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More